Evidence map›Paper›PMID 36479121›Full record

ArticleFrontiers in immunology2022

Hijacking the human complement inhibitor C4b-binding protein by the sporozoite stage of the

Ayman Khattab, Mikel Rezola, Marta Barroso, Mikael Kyrklund, Tero Pihlajamaa, Tobias L Freitag, Geert-Jan van Gemert, Teun Bousema, Perttu Permi, Ossi Turunen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Diverse Functions of C4b-Binding Protein in Health and Disease.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 5 countries.

Ayman KhattabDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Mikel RezolaDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Marta BarrosoDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Mikael KyrklundDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Tero PihlajamaaDepartment of Clinical Chemistry, HUSLAB, Helsinki University Hospital, HUS Diagnostic Center, Helsinki, Finland.
Tobias L FreitagDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Geert-Jan van GemertDepartment of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.
Teun BousemaDepartment of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.
Perttu PermiDepartment of Chemistry, Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Ossi TurunenDepartment of Bioproducts and Biosystems, Aalto University, Espoo, Finland.
Robert SauerweinTropIQ Health Sciences, Nijmegen, Netherlands.
Adrian J F LutyUniversité de Paris, MERIT, IRD, Paris, France.
Seppo MeriDepartment of Bacteriology and Immunology, Haartman Institute, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIAalto University · FICity of Scientific Research and Technological Applications · EGHelsinki University Hospital · FIInstitut de Recherche pour le Développement · FRRadboud University Medical Center · NLRadboud University Nijmegen · NLTropIQ Health Sciences · NLUniversity of Jyväskylä · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is considered the first line of defense against pathogens. Hijacking complement regulators from blood is a common evasion tactic of pathogens to inhibit complement activation on their surfaces. Here, we report hijacking of the complement C4b-binding protein (C4bp), the regulator of the classical and lectin pathways of complement activation, by the sporozoite (SPZ) stage of the

Indexed as

ParasitesVaccinesAnimalsComplement C4b-Binding ProteinComplement Inactivating AgentsHumansPeptidesPlasmodium falciparumSporozoitesC4BPA protein, humanComplement C4b-Binding ProteinComplement Inactivating AgentsPeptidesVaccinesC4b binding proteincircumsporozoite proteincomplement evasionPlasmodiumsporozoites

Identifiers

PMID36479121
PMCPMC9720182
OpenAlexW4309746999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.